Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what to expect. Gilead Sciences beat analysts’ revenue expectations by 7. ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' revenue ...

Gilead Sciences handily beat the consensus Wall Street earnings estimate for Q4. The company projects much higher earnings in full-year 2025. Income and value investors could like this biotech stock.

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results, a robust HIV franchise, and an imminent lenacapavir commercialization by summer 2025. Lenacapavir PrEP regimen, with 100% ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments. A key highlight was the robust performance in the HIV and oncology segments ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company’s Board of Directors has declared an increase of 2.6% in the company’s quarterly cash dividend, beginning in the first ...

FOSTER CITY, Calif. — FOSTER CITY, Calif. — Gilead Sciences Inc. (GILD) on Tuesday reported fourth-quarter earnings of $1.78 billion. The Foster City, California-based company said it had net ...

Gilead Beats Q4 Estimates With 7% Sales Growth, Driven by HIV and Oncology. Company Projects Strong 2025 Earnings, Eyes Lenacapavir Launch for HIV Prevention. Get two weeks of free access to pro ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD – Research Report) and Exelixis (EXEL – Research Report). Gilead Sciences ...

(RTTNews) - Gilead Sciences Inc. (GILD) revealed earnings for its fourth quarter that increased from the same period last year The company's earnings totaled $1.7 billion, or $1.42 per share.

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $115.00. The company’s shares closed ...

With Gilead Sciences' long-acting lenacapavir unlocking a reinvigorated focus on the pre-exposure prophylaxis (PrEP) market and growth in its three therapeutic areas driving momentum beyond HIV ...